Orasis Pharmaceuticals announced that it will present new data on its novel eye drop candidate, CSF-1, at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) annual meeting being held April 22-26 in Washington, D.C.

"We look forward to these presentations by leading global ophthalmologists during the 2022 ASCRS Annual Meeting, which will provide insights into the efficacy, safety, and comfort of CSF-1 and its potential as a treatment option for presbyopia," Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals, said in a company news release. "These new data underscore Orasis' commitment to reshaping vision possibilities for millions of people living with this age-related condition in the U.S., and even more across the globe."

Researchers will present data from the phase 2b clinical trial, a multicenter, double-masked, parallel group study, which evaluated the efficacy, safety, and comfort of CSF-1 ophthalmic solution as a potential novel treatment for presbyopia. Data presented will also include a post hoc analysis, which assessed sustained improvement in functional near vision (20/40 or better) with CSF-1 versus vehicle in one or both eyes.

Details about Orasis Pharmaceuticals' ASCRS Paper Sessions presentations are as follows:

Phase 2b Clinical Trial to Evaluate the Safety and Efficacy of CSF-1 for the Treatment of Presbyopia 
Session: SPS-316 Presbyopia Correction: New Treatments and Studies
Presentation Date/Times: Monday, April 25, 2022, from 4:35 - 4:40 p.m. ET
Location: WEWCC - Level 1, 143C
Presenter: Marjan Farid, MD, ABO

CSF-1 Demonstrates Sustained Improvement in Binocular Functional Near Vision in Participants with Presbyopia 
Session: SPS-316 Presbyopia Correction: New Treatments and Studies
Presentation Date/Times: Monday, April 25, 2022, from 4:40 - 4:45 p.m. ET
Location: WEWCC - Level 1, 143C
Presenter: Preeya K. Gupta, MD